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Dengue Is a Serious Public Health Problem
Dengue virus (DV) infections cause undisputedly the most
important arthropod-borne viral disease in terms of worldwide
prevalence, human suffering, and cost. Worldwide DV infection
prevalence in 2010 was between 284 to 528 million cases [1].
Approximately 84% of these cases come from Asia and the
Americas, where the cost for emerging economies can be as high
as 580 million dollars per year [2]. Thus, the need for an efficient
vaccine against DV is extreme.
While up to 90% of dengue cases are either asymptomatic or
cause an underreported, self-limited, flu-like illness, symptomatic
DV infection manifests as two main clinical forms: 1) dengue fever
(DF) and 2) severe dengue (SD). DF symptoms include high-degree
fever, headache, myalgia with arthralgia, retro-orbital pain, and
rash. SD evolves clinically as a life-threatening complication from
DF. SD is characterized by plasma leakage, hemoconcentration,
hemorrhagic shock, and organ failure, which may lead to patient
death. Any of the four described DV serotypes can be responsible
for either DF or SD, although the precise mechanisms leading to
SD are still unclear. Evidence suggests factors such as viral
virulence, host gene background, and secondary DV infections
contribute to the exacerbation of the disease. In consequence,
preventive strategies through vaccination must consider tetravalent
formulations.
Dengue Virus Is a Flavivirus
The Flaviridae family, of which DV is a member, consists of
enveloped, positive-stranded RNA viruses. The flavivirus genome
encodes a polyprotein, which is processed by cellular and viral-
encoded proteases into ten proteins (Figure 1A–B). The virion core
contains the viral genome encased in the capsid (C) protein. The
virion membrane contains two virus-coded type I membrane
glycoproteins. The larger envelope (E) protein is essential for viral
attachment and entry and is also the main target of neutralizing
antibodies. The membrane protein (M) is synthesized as a precursor
protein (prM) that is processed during export; it prevents E
conformational changes from occurring during viral assembly.
Besides these three structural proteins (C-prM-E), the viral genome
codes for seven nonstructural proteins important for viral replica-
tion, translation, and the proteolytic processing of the polyprotein.
Since E is exposed on the virion surface, it contains the epitopes
recognized by neutralizing antibodies and its gene is responsible
for the genetic variation resulting in four DV serotypes [3]. The
mature flavivirus virion particle has a herringbone array of 90
tightly packed E glycoprotein dimers parallel to the virion surface.
Each 500-amino-acid E monomer contains a 400-amino-acid N-
terminal ectodomain that folds into three structural domains. It
has been posited that antibodies directed against domain III are of
highly specific neutralizing capacity, while antibodies directed
against the other two domains, neutralizing to some extent, can
cross-react with other DV serotypes.
The Ideal DENV Vaccine
Vaccination has been the most desired strategy for controlling
the spread of DV. Neutralizing antibodies directed against
mosquito-borne flavivirus envelopes can prevent the development
of infectious disease. This has been beautifully illustrated by the
development of successful vaccines against other related mosquito-
borne flaviviruses with similar structure, specifically the attenuated
strain 17D vaccine against yellow fever virus (YFV) and the
attenuated strain 14-14-2 against Japanese encephalitis virus
(JEV), both obtained by serial passage in cell culture. Importantly,
for both vaccines, a neutralization titer of at least 1:10 is protective.
Thus, the most useful and documented correlate of protection for
flaviviruses is the presence of neutralizing antibodies assayed by
the plaque reduction neutralization assay (PRNA).
Why then has the development of a DV vaccine proven so
challenging? Natural DV infection triggers a robust, neutralizing
immunity that provides an apparently life-long protection against
the infecting DV serotype and a short-lived (months) cross-
protection against heterologous DV serotypes. Interestingly, the
humoral response to DV not only mediates protection though viral
neutralization, but also seems to play a major role in the
development of more severe forms of dengue disease. Dengue
hemorrhagic fever and dengue shock syndrome (DHF/DSS) cases
are often associated with secondary DV infections with a
heterologous DV serotype. Subneutralizing, heterotypic antibodies
induced during a primary infection with one serotype of DV form
complexes with a different serotype of DV during secondary
infection, enhancing uptake of infectious particles by Fc-receptor–
bearing permissive cells. This phenomenon, called antibody-
dependent enhancement (ADE), results in an increased number of
infected cells and a higher viremia that, combined with a pro-
inflammatory cytokine response from an enhanced infection of
macrophage and dendritic cells, have been related with SD [4].
Furthermore, antibodies to the precursor form of M, the prM
protein, can also induce ADE [5]. Since an important fraction of
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viral particles in patients’ blood are ‘‘immature,’’ displaying prM
on their surface, these may become fully infective in the presence
of anti-prM antibodies. Thus, ADE reinforces the necessity for a
tetravalent DV vaccine preparation, a requirement that has been a
significant obstacle to successful vaccine development. The
realistic approach toward this goal has consisted of developing
monovalent vaccines capable of inducing homotypic protection,
and subsequently combining them into a tetravalent formulation.
However, the induction of a strong and balanced protective
immunity against the four DV serotypes to avoid the potential risk
of ADE after vaccination has been challenging. Several DV
vaccines are currently in different stages of development; due to
space constraints, we will refer to those of significant interest.
Attenuated and Recombinant DV Vaccine
Candidates
Attenuating DV is a quest that has lasted more than 60 years
[6]. Classic attenuation by serial passage in cell lines different from
the traditional animal host has been achieved for DV. The balance
between safe attenuation and robust immunogenicity is achieved
differently for each DV serotype. In particular for DV2, after 53
passages in primary dog kidney cells (PDK53) the virus lost its
capability to induce viremia in nonhuman primates, while
stimulating robust neutralizing immune responses [7]. After
almost two decades of experimentation we have corroborated
that reactogenicity is associated with an insufficient passage
history, learned that dose components and the time between
multiple doses are of paramount importance to obtain balanced
immunity against the four serotypes, and that a formulation that
causes fever in adults is probably safe to use in children. Recently,
a phase II clinical trial in 86 adult volunteers documented safety
and an acceptable immunogenicity that was higher in individuals
with prior DV or other flavivirus contact history [8].
As an alternative to attenuation by serial passages, DV can also
be attenuated by targeted mutagenesis. Deletion of 30 nucleotides
(D30) in the 3’ end of the DV1 and DV4 RNA genome results in a
reduction of viral replication fitness while maintaining immuno-
genicity [9]. Swapping the entire 3’ nontranslated region of DV3
with that of DV4 D30 attenuated the virus. DV2 was attenuated
by chimerization using the replication machinery of DV4 D30. A
phase I clinical trial of tetravalent vaccine formulations (TetraVax-
DV) using these immunogens was conducted in flavivirus-naı¨ve
adults and reported recently [10]. Close to 90% seropositivity to all
serotypes except DV2 was obtained after a single dose. Viremia
after vaccination correlated with a trivalent immunity.
A major breakthrough in DV vaccine research came with the
demonstration that mosquito-borne flaviviruses may replicate as
chimeric viruses in which the envelope genes M and E of an
attenuated vector genome are replaced with the cognate genes of
the target virus. This strategy, depicted in Figure 1C, has resulted
in two different types of chimeras important in DV-attenuated
vaccines:
I. Using the replication machinery of the YFV 17D vaccine
strain, Chimerivax displays each of the four DV serotype
glycoproteins in a separate functional viral particle. It
constitutes the most advanced vaccine candidate to be tested
in humans so far. This vaccine showed promising results in
phase I clinical trials in endemic and nonendemic countries.
Figure 1. Dengue virus structure. A. DV virions are enveloped, containing three structural proteins; the envelope (E) and membrane (M) proteins
(dark and light blue, respectively) are anchored to the viral membrane (green), and the capsid protein (C) (orange) covers the viral genome (red)
(kindly provided by Dr. Richard J. Kuhn). B. The dengue genome is a single-stranded, positive-polarity RNA with a unique open reading frame flanked
by 59 and 39 untranslated regions (UTR). It encodes for three structural and seven nonstructural proteins, represented by colored, stylized boxes. The
name of DV viral proteins is indicated. C. Diagram of chimeric DV vaccine approach. Chimeric flaviviruses are constructed by swapping the prM and E
coding sequences from an attenuated backbone for those of a heterologous DV strain. Viral RNA is obtained in vitro and transfected. Vero cells are
used to amplify the infectivity of the chimeric virus, which is formed by the respective DV serotype envelope proteins with the replication machinery
(represented by gears) of an attenuated, related flavivirus.
doi:10.1371/journal.ppat.1003551.g001
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However a phase IIb clinical trial in 2,669 Thai schoolchil-
dren with a tetravalent vaccine showed poor efficacy (30.3%,
95% CI - 13.4 to 56.6) of protection against febrile DV
infections [11]. Subjects received three doses at zero, six, and
12 months and were monitored for up to two years after the
first dose. While one or more doses of the vaccine reduced
incidence of DV1, DV3, and DV4 by 90%, an efficacy of
only 9.2% (95% CI -75.0 to 51.3) was observed for DV2,
which negatively impacted the overall protection. Regretta-
bly, fewer than 5% of vaccinees and control subjects were
studied serologically for DV neutralization after completion
of the vaccine schedule. Interestingly, after two years of
incomplete protection against the four serotypes no enhanced
DV infectious disease was documented, which suggests that
trivalent immunity may prevent the development of SD and
underscores the need to revisit ADE theoretical risk among
vaccinees.
II. The other chimeric construction approach uses the replica-
tion machinery of the aforementioned attenuated DV2
PDK53 vaccine candidate. Again, the relevant DV envelope
glycoproteins are displayed on the surface of the chimeric
particle. The tetravalent formulation (DENvax) is currently in
a dose-escalating, phase I clinical trial (ClinicalTrial.gov
identifier NCT01224639).
Inactivated and Subunit Vaccines
There are two successful examples of inactivated vaccines
against related arthropod-borne flaviviruses, tick-borne encepha-
litis, and JEV. This strategy is appealing for the pursuit of a DV
vaccine because an inactivated vaccine is unlikely to elicit
imbalanced immune responses stemming from infection interfer-
ence. Protective immune responses in macaques after three doses
of a concentrated, formalin-inactivated, alum-adjuvanted DV2
vaccine (PIV for purified, inactivated vaccine) candidate have been
documented [12]. Furthermore, PIV immunogenicity and protec-
tive ability when administered in complex with modern, propri-
etary AS05 and AS08 adjuvants was comparable to a single dose
of corresponding live-attenuated vaccine [13].
Subunit vaccines have also been explored. Immunization with
an insect-expressed E protein ectodomain from DV2 is capable of
inducing protection in macaques [14]. Once again, the use of
adjuvants seems important to achieve robust immunity via this
mechanism. A phase I clinical trial, designed to assess the safety of
alum-adjuvanted DV1 E antigen, in sixteen adult volunteers, has
been concluded and is pending publication of results (Clinical-
Trial.gov identifier NCT00936429).
In summary, the strength and longevity of neutralizing
immune responses elicited by attenuated vaccines outperforms
responses observed with replication-defective approaches. Still,
safety and the possibility of combining vaccine components
without the possibility of viral interference adds enthusiasm for
the latter approach. Interestingly, the potential for a prime-boost
schedule was assessed in primate model [15]. In this report,
macaques received a single dose of a tetravalent PIV vaccine and
then a derivative, tetravalent, attenuated formulation two months
later. All of the animals developed a solid immunity against the
four DV serotypes documented by the absence of viremia
following a wild-type challenge six months after the last vaccine
dose.
Challenges in the Quest for a Dengue Vaccine
There are two main windows of opportunity to build upon
toward realizing efficient vaccination for DV. First, a clinically
relevant animal model for dengue infection and vaccine develop-
ment is lacking. Rhesus monkeys do not show clinical signs of
infection after a wild-type DV challenge; instead the intensity and
length of viremia serves as a proxy to infer protection. Second,
rigorous correlates of protection have not been established for DV.
The best available indicator of immunogenicity is the titration of
neutralizing antibodies, however titration of plaque reduction
neutralization antibodies has not been promoted to a bona fide
correlate of protection because of ambiguous results pertaining to
the protective titer. Testing the protection efficiency of tetravalent
vaccine candidates in volunteers may answer both questions.
Results from the first human DV challenge experiments have been
recently published and demonstrate the viability of this approach
[16]. Paraphrasing Vesalius, DV vaccine development may have
been ‘‘deceived by monkeys’’ but is on the right path to become a
huge benefit for mankind.
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